Ron Do, PhD, associate professor, Charles Bronfman Institute for Personalized Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, discuss their hopes for their findings and how genetic data are being used in health care.
Ron Do, PhD, associate professor, Charles Bronfman Institute for Personalized Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, discuss how they hope their recent study findings on penetrance of pathogenic and loss-of-function clinical variants can be used and how genetic data are being used in health care.
Transcript
How do you hope the results of your study will be used?
Do: I'll just say, for this study, we wanted to bring attention to the fact that penetrance appeared variable but generally low and penetrance wasn't necessarily concordant with pathogenicity labels. Penetrance doesn't necessarily mean the same thing as pathogenicity.
Forrest: Adding onto that, we also hope that this study will raise important discussions and dialogue about whether a new type of classification system—one based on penetrance, perhaps—to assess disease risk of variants is warranted and this could actually complement the current system based on pathogenicity, which is a categorical system.
Are we approaching any milestones in the understanding of genetic variants?
Do: We feel that this study is a good first step to understanding the disease risk, or penetrance, of genetic variants. However, more research is needed to calculate penetrance in a much larger number of samples to obtain more accurate penetrance estimates at the variant level.
Forrest: The milestone that we're hitting is that genetic data are being used increasingly inside health care. Improving the precision of our interpretations of variants with penetrance will aid in the integration of an individual's genetic data in their health care and help achieve personalized medicine, whereby an individual's unique sequence of DNA can actually shape their clinical care.
Early Detection Strategies for Interstitial Lung Disease in Rheumatology: Janet Pope, MD, MPH
August 11th 2025Janet Pope, MD, MPH, discusses screening and diagnostic approaches for interstitial lung disease in patients with systemic sclerosis, rheumatoid arthritis, and other connective tissue diseases.
Read More
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
AI Meets Medicare: Inside CMS’s WISeR Model With Sanjay Doddamani, MD, MBA, Part 2
August 5th 2025In this second part of his interview with The American Journal of Managed Care®, Sanjay Doddamani, MD, MBA, a former senior advisor to CMMI and founder and CEO of Guidehealth, continues a dialogue on the future of value-based care and the promise—and limits—of AI-enabled innovation, reflecting on challenges like rising Medicare costs and patients’ growing financial burdens.
Read More
It Take a Village in Cancer Care: A Q&A With David Nguyen, MD
July 23rd 2025David Nguyen, MD, medical oncologist with Tufts Medicine and Lowell General Hospital, discusses the evolving landscape of advanced cancer treatments like chimeric antigen receptor T-cell therapy and bispecific antibodies
Read More